Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aeterna Zentaris Inc T.AEZS

Alternate Symbol(s):  AEZS

Healthcare Biotechnology
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The... see more

Recent & Breaking News (TSX:AEZS)

Aeterna Zentaris Files Additional Patent Application to Strengthen IP Protection of Zoptarelin Doxorubicin

Canada NewsWire April 16, 2015

Aeterna Zentaris Announces Plans to Initiate Phase 3 Study of Macrilen(TM) in AGHD Following Successful Meeting with FDA

Canada NewsWire April 13, 2015

Aeterna Zentaris Signs Transfer Agreement of its Discovery Library with the Medical University of South Carolina

Canada NewsWire March 31, 2015

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2014 Financial and Operating Results

Canada NewsWire March 17, 2015

Aeterna Zentaris Announces Closing of US$37 Million Public Offering of Common Shares and Warrants

Canada NewsWire March 11, 2015

Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2014 Financial and Operating Results on March 17, 2015

PR Newswire March 10, 2015

Aeterna Zentaris Announces Pricing of US$37 Million Public Offering of Common Shares and Warrants

Canada NewsWire March 6, 2015

Aeterna Zentaris Announces Proposed Public Offering of Common Shares and Warrants

Canada NewsWire March 5, 2015

Aeterna Zentaris to Present at Roth Conference 2015

Canada NewsWire March 2, 2015

UPDATE - MONDAY DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors Of Class Action Against Aeterna Zentaris Inc. And Its Board Of Directors And A Lead Plaintiff Deadline Of January 12, 2015 -- AEZS

PR Newswire January 9, 2015

Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against Aeterna Zentaris Inc. and Lead Plaintiff Deadline of January 12, 2015

PR Newswire January 8, 2015

INVESTOR ALERT: Glancy Binkow & Goldberg LLP Announces an Expanded Class Period in the Shareholder Lawsuit Against Aeterna Zentaris Inc.

Business Wire January 6, 2015

EQUITY UPDATE: Rosen Law Firm Expands Class Period in Aeterna Zentaris, Inc. Investor Class Action to Include Purchasers Between April 2, 2012 and November 6, 2014 - AEZS

Business Wire January 6, 2015

INVESTOR ALERT: Investors of Aeterna Zentaris Inc. With Losses of $100,000 or More Are Encouraged to Contact Law Offices of Howard G. Smith

Business Wire January 6, 2015

Aeterna Zentaris to Present at Upcoming Biotech Showcase Conference in San Francisco

Canada NewsWire January 6, 2015

SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Aeterna Zentaris Inc. and Its Board of Directors and a Lead Plaintiff Deadline of January 12, 2015

Business Wire January 5, 2015

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Aeterna Zentaris, Inc. of Class Action Lawsuit and Upcoming Deadline -- AEZS

GlobeNewswire January 3, 2015

SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Aeterna Zentaris Inc. and Its Board of Directors and a Lead Plaintiff Deadline of January 12, 2015 -- AEZS

GlobeNewswire December 29, 2014

Aeterna Zentaris: Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin in Prostate Cancer Published in Clinical Cancer Research

Canada NewsWire December 29, 2014

SECURITIES ALERT: Rosen Law Firm Reminds Aeterna Zentaris, Inc. Investors of Important January 12, 2015 Deadline in Class Action Filed by the Firm -- AEZS

GlobeNewswire December 28, 2014